BioCentriq Strengthens Partnership With Pluristyx To Accelerate The Development Of iPSC-Derived NK Cell Therapies

BioCentriq, Inc., a global cell therapy Contract Development and Manufacturing Organization (CDMO), is proud to announce a significant enhancement to its partnership with Pluristyx Inc., an early stage, privately held biotechnology company specializing in Induced Pluripotent Stem Cell (iPSC) products. Through BioCentriq’s process development services, their strategic collaboration now includes seamless access to Pluristyx's proprietary iPSC lines to help lower the barrier to entry, provide a swift translation to clinic, and ensure the best path to commercialization for the next generation of iPSC-derived treatments.

Pluristyx's unique clinical-grade iPSC lines, derived from regulatory-compliant starting material and reprogrammed using proprietary mRNA technology, represent a breakthrough in cell therapy development, providing stability, scalability, and customization potential for enhanced therapeutic outcomes. Building upon the existing research agreement, BioCentriq will extend its capabilities by incorporating Pluristyx's iPSC lines into its cell therapy development and manufacturing processes. This expansion aims to facilitate an integration of Pluristyx's proprietary iPSC lines, further optimizing the activation, expansion rate, and manufacturability of iPSC-derived NK cells.

"Expanding our collaboration with Pluristyx to include access to iPSC lines is a significant leap forward for BioCentriq and our clients," said Alex Klarer, Vice President of Business Strategy and Innovation at BioCentriq. "This capability enhancement underscores BioCentriq’s commitment to providing our clients with state-of-the-art resources to accelerate the development and manufacture of innovative cell-based therapies including next-generation iPSC-derived treatments.”

“Pluristyx is excited to expand our relationship with BioCentriq to provide streamlined access to our research- and clinical-grade iPSC lines and accelerate the development of next generation therapeutics,” states Dr Benjamin Fryer, Chief Executive Officer and Co-Founder of Pluristyx. “Our best-in-class iPSC lines offer a simplified path to commercialization, and are made available pre-edited with our exclusive FailSafe and iACT Stealth Cells platform technologies to provide unparalleled safety and cloaking capabilities to overcome the inherent challenges of iPSC-derived therapies.”